Dermorphin

Dermorphin is a naturally occurring compound from certain tree frogs. It can strongly reduce pain and create calming effects. It works on the same body systems as morphine but may last longer and need only very small amounts to show effects in research settings.

Description

• Dermorphin is a natural heptapeptide originally isolated from the skin of South American tree frogs (Phyllomedusa species).
• Acts as a potent μ-opioid receptor agonist with strong analgesic effects in animal models.
• Exhibits far greater affinity for μ-receptors than morphine while producing less respiratory depression in early research.

How It Works

• Binds selectively to μ-opioid receptors in the central and peripheral nervous system.
• Inhibits pain-signal transmission and alters perception of nociceptive stimuli.
• May trigger endorphin-mediated analgesia with longer duration than morphine in preclinical settings.

Documented Effects

• Produces powerful analgesia in animal testing at microgram doses.
• Demonstrates prolonged pain-relief effects compared to standard opioids.
• Limited data exist on human pharmacokinetics; use restricted to laboratory research.

Theoretical Effects

• Potential model compound for designing new pain-control agents with fewer side effects.
• Not intended for therapeutic or clinical use; data limited to experimental research.

Pharmacokinetics

• Half-life: approximately 2–4 hours in animal models.
• Time to peak concentration: 10–30 minutes after administration.
• Steady-state: not reached due to short-acting nature and single-dose research use.

Duration of Effects

• Analgesic effects typically last 3–6 hours depending on dose and model species.
• May exhibit residual calming or sedative effects beyond peak pain relief.
• No sustained effects beyond 12 hours post-administration in preclinical trials.

Reconstitution

• Use only bacteriostatic water to mix the lyophilized powder.
• Example vial: 10 mg of Dermorphin
• Choose reconstitution volume based on dosing convenience:
  • 1 mL water → 10 mg/mL → 1 mg per 10 units
  • 2 mL water → 5 mg/mL → 500 mcg per 10 units
  • 4 mL water → 2.5 mg/mL → 250 mcg per 10 units
• Swirl gently to dissolve; avoid shaking.
• Refrigerate reconstituted solution (2–8 °C). Use within ~14 days for best stability.

Injectable Dosage Overview (First-Time Use)

Typical Starting Dose

• Injectable (research use only): 50–200 mcg subcutaneous (SC) or intramuscular (IM) per session.
• Conservative start: 50 mcg to evaluate response and tolerance.

Common Therapeutic Range

• Research range: 100–400 mcg per administration depending on target and model.
• Used exclusively for receptor and analgesia studies in controlled environments.

Maximum Session Dose

• Anecdotal ceiling: ~500 mcg per injection.
• Higher doses increase risk of sedation and respiratory depression in animal models.

Standard Cycle Length

• Short-term study compound; not intended for repeated or chronic administration.
• Washout periods recommended between exposures in research protocols.

Clinical Notes

• Administered via SC or IM injection in microgram doses for laboratory pain-model testing.
• No tapering or stacking protocols applicable due to short duration and potency.
• Stable for about 14 days when refrigerated (2–8°C). Protect from light and heat. Avoid freezing.
• Not to be combined with any opioid or sedative agents in research models.

Safety Notes (First-Time Use)

• Handle under laboratory conditions only.
• Possible effects: drowsiness, slowed respiration, or bradycardia at higher doses.
• Do not combine with other opioid or CNS-depressant agents.
• No approved clinical or veterinary use.